Factors Influencing Persistence of Diphtheria Immunity and Immune Response to a Booster Dose in Healthy Slovak Adults
Marek Petráš,
Vladimir Oleár,
Milica Molitorisová,
Jana Dáňová,
Alexander M. Čelko,
Elena Nováková,
Mária Štefkovičová,
Zuzana Krištúfková,
Jana Malinová,
Ivana Králová Lesná
Affiliations
Marek Petráš
Preventive Medicine, Third Faculty of Medicine, Charles University in Prague, 100 00 Prague, Czech Republic
Vladimir Oleár
Faculty of Healthcare, Alexander Dubček University of Trenčín, 911 50 Trenčín, Slovakia
Milica Molitorisová
Faculty of Pharmacy, Comenius University in Bratislava, 832 32 Bratislava, Slovakia
Jana Dáňová
Preventive Medicine, Third Faculty of Medicine, Charles University in Prague, 100 00 Prague, Czech Republic
Alexander M. Čelko
Preventive Medicine, Third Faculty of Medicine, Charles University in Prague, 100 00 Prague, Czech Republic
Elena Nováková
Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 01 Martin, Slovakia
Mária Štefkovičová
Faculty of Healthcare, Alexander Dubček University of Trenčín, 911 50 Trenčín, Slovakia
Zuzana Krištúfková
Faculty of Public Health, Slovak Medical University in Bratislava, 831 01 Bratislava, Slovakia
Jana Malinová
Preventive Medicine, Third Faculty of Medicine, Charles University in Prague, 100 00 Prague, Czech Republic
Ivana Králová Lesná
Laboratory for Atherosclerosis Research, Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic
We assessed the long-term persistence of humoral immunity against diphtheria in adults with childhood vaccination and the immunogenicity of a booster dose considering demographic, behavioural and vaccinating factors. We conducted a trial in 200 healthy Slovak adults aged 24−65 years, immunised against diphtheria in childhood and against tetanus at regular 10−15 year intervals, and receiving a dose of a tetanus-diphtheria toxoid vaccine. The response was determined by ELISA antibody concentrations of paired sera before and at 4 weeks post-vaccination. A seroprotection rate of 21% (95% confidence interval, CI 15.6−27.3%) was found in adults up to 59 years since the last vaccination with seroprotective levels of antibodies against diphtheria ≥0.1 IU/mL and a geometric mean concentration of 0.05 IU/mL. Conversely, seropositive levels ≥0.01 IU/mL were observed in 98% of adults (95% CI 95−99.5%). Booster-induced seroprotection was achieved in 78% of adults (95% CI 71.6−83.5%) clearly depending on pre-booster antibody levels correlating with age and time since the last vaccination. Moreover, only 54.2% of smokers and 53.3% of patients on statins exhibited seroprotection. Booster vaccination against diphtheria was unable to confer seroprotection in all recipients of only childhood vaccination.